BC Extra | Sep 6, 2019
Company News

Management tracks: Prometheus, Step, Spero, NorthSea, Aristea, MODAG and more

Salix’s Mark McKenna will become CEO of gastroenterology and autoimmune disease company Prometheus Biosciences Inc. (San Diego, Calif.), formerly known as Precision IBD Inc. McKenna was president at Salix Pharmaceuticals Ltd., a subsidiary of Bausch...
BC Extra | Apr 25, 2019
Company News

Salix licenses S1P receptor modulator from Mitsubishi

Mitsubishi has found a new partner for its oral S1P receptor modulator in Salix, two years after Biogen decided to return its rights to the compound. Salix Pharmaceuticals Ltd. gained exclusive rights Thursday to develop...
BC Extra | Apr 1, 2019
Company News

Salix licenses new NASH target from UCLA

Salix is entering the NASH and NAFLD race with a license from UCLA to a compound against a new target in the space. Salix Pharmaceuticals Ltd. gained a license to develop and commercialize a fusion...
BC Extra | Jan 5, 2019
Company News

Flurry of management moves on eve of JPM

More than 30 biopharma companies announced executive changes to kick off the New Year, including Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Immunocore Ltd. (Abingdon, U.K.), both of which brought on former AstraZeneca plc (LSE:AZN; NYSE:AZN) executives...
BC Week In Review | Feb 16, 2018
Clinical News

FDA prolongs review of Valeant's bowel cleansing agent

The Salix Pharmaceuticals Ltd. subsidiary of Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) and partner Norgine B.V. (Amsterdam, the Netherlands) said FDA extended by three months its review of an NDA for Plenvu (NER1006) for bowel...
BC Week In Review | Jun 16, 2017
Company News

GeneriCo wins IPR for Apriso

In a May inter partes review (IPR) proceeding, the U.S. Patent Trial and Appeal Board (PTAB) invalidated all claims in U.S. Patent 8,865,688 covering ulcerative colitis (UC) drug Apriso granulated mesalamine from Valeant Pharmaceuticals International...
BioCentury | Jan 6, 2017
Finance

Good riddance

  Investors aren’t lamenting the end of 2016, but they are pinned between anxiety and optimism for the year ahead. The anxiety stems from uncertainty about U.S. government policies for healthcare under the new administration....
BC Extra | Nov 1, 2016
Company News

Valeant gains after Salix rumors

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) added $6.02 (34%) to $23.86 on Tuesday after media reports said it was discussing a sale of its Salix Pharmaceuticals gastroenterology business for about $10 billion. The reports named...
BC Week In Review | Sep 12, 2016
Company News

Valeant Pharmaceuticals sales and marketing update

Valeant launched an oral formulation of Relistor methylnaltrexone in the U.S. to treat opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. The wholesale acquisition cost (WAC) for a 150 mg tablet is $16.67....
BC Week In Review | Aug 22, 2016
Company News

Valeant Pharmaceuticals, Pharming deal

Pharming will pay Valeant $60 million up front and up to $65 million in sales milestones to reacquire North American commercialization rights to Ruconest conestat alfa. The recombinant human C1 esterase inhibitor is approved in...
Items per page:
1 - 10 of 630
BC Extra | Sep 6, 2019
Company News

Management tracks: Prometheus, Step, Spero, NorthSea, Aristea, MODAG and more

Salix’s Mark McKenna will become CEO of gastroenterology and autoimmune disease company Prometheus Biosciences Inc. (San Diego, Calif.), formerly known as Precision IBD Inc. McKenna was president at Salix Pharmaceuticals Ltd., a subsidiary of Bausch...
BC Extra | Apr 25, 2019
Company News

Salix licenses S1P receptor modulator from Mitsubishi

Mitsubishi has found a new partner for its oral S1P receptor modulator in Salix, two years after Biogen decided to return its rights to the compound. Salix Pharmaceuticals Ltd. gained exclusive rights Thursday to develop...
BC Extra | Apr 1, 2019
Company News

Salix licenses new NASH target from UCLA

Salix is entering the NASH and NAFLD race with a license from UCLA to a compound against a new target in the space. Salix Pharmaceuticals Ltd. gained a license to develop and commercialize a fusion...
BC Extra | Jan 5, 2019
Company News

Flurry of management moves on eve of JPM

More than 30 biopharma companies announced executive changes to kick off the New Year, including Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Immunocore Ltd. (Abingdon, U.K.), both of which brought on former AstraZeneca plc (LSE:AZN; NYSE:AZN) executives...
BC Week In Review | Feb 16, 2018
Clinical News

FDA prolongs review of Valeant's bowel cleansing agent

The Salix Pharmaceuticals Ltd. subsidiary of Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) and partner Norgine B.V. (Amsterdam, the Netherlands) said FDA extended by three months its review of an NDA for Plenvu (NER1006) for bowel...
BC Week In Review | Jun 16, 2017
Company News

GeneriCo wins IPR for Apriso

In a May inter partes review (IPR) proceeding, the U.S. Patent Trial and Appeal Board (PTAB) invalidated all claims in U.S. Patent 8,865,688 covering ulcerative colitis (UC) drug Apriso granulated mesalamine from Valeant Pharmaceuticals International...
BioCentury | Jan 6, 2017
Finance

Good riddance

  Investors aren’t lamenting the end of 2016, but they are pinned between anxiety and optimism for the year ahead. The anxiety stems from uncertainty about U.S. government policies for healthcare under the new administration....
BC Extra | Nov 1, 2016
Company News

Valeant gains after Salix rumors

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) added $6.02 (34%) to $23.86 on Tuesday after media reports said it was discussing a sale of its Salix Pharmaceuticals gastroenterology business for about $10 billion. The reports named...
BC Week In Review | Sep 12, 2016
Company News

Valeant Pharmaceuticals sales and marketing update

Valeant launched an oral formulation of Relistor methylnaltrexone in the U.S. to treat opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. The wholesale acquisition cost (WAC) for a 150 mg tablet is $16.67....
BC Week In Review | Aug 22, 2016
Company News

Valeant Pharmaceuticals, Pharming deal

Pharming will pay Valeant $60 million up front and up to $65 million in sales milestones to reacquire North American commercialization rights to Ruconest conestat alfa. The recombinant human C1 esterase inhibitor is approved in...
Items per page:
1 - 10 of 630